CA-5f|cas:1370032-19-1|西域试剂

CA-5f,99.40%

产品编号：Bellancom-112698| CAS NO：1370032-19-1| 分子式：C₂₄H₂₄N₂O₃| 分子量：388.46

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-112698	￥1100.00	杭州北京（现货）
Bellancom-112698	￥1800.00	杭州北京（现货）
Bellancom-112698	￥3800.00	杭州北京（现货）
Bellancom-112698	￥6800.00	杭州北京（现货）
Bellancom-112698	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CA-5f

产品介绍

CA-5f 是一种有效的晚期巨自噬/自噬 (macroautophagy/autophagy) 抑制剂，通过抑制自噬体-溶酶体融合起作用。CA-5f 能够增加 LC3B-II (一种监控自噬的标记物) 和 SQSTM1 蛋白水平，促进 ROS 的产生。具有抗肿瘤活性。

生物活性

CA-5f is a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II (a marker to monitor autophagy) and SQSTM1 protein, and also increases ROS production. Anti-tumor activity.

体外研究

CA-5f (0-40 μM, 6 hour) concentration- and time-dependently elevates the level of LC3B-II (a marker to monitor autophagy) and SQSTM1 protein both in A549 cells and HUVECs.
CA-5f (20 μM, 6 hours) inhibits the degradation of autophagosomes when treated alone or in combination Bafilomycin A1 (100 nM) or Chloroquine (30 μM) in A549 cells and HUVECs.
CA-5f (20 μM) neither impairs the hydrolytic function nor the quantity of lysosomes.
CA-5f (20 μM, 96 hours) inhibits the growth of A549 cells, and less cytotoxic to normal HUVECs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	A549, HUVECs
Concentration:	20 μM
Incubation Time:	96 hours
Result:	Exhibited more cytotoxicity against A549 cells compared with normal HUVECs.

Western Blot Analysis

Cell Line:	A549 cells and HUVECs
Concentration:	0-40 μM
Incubation Time:	6 hours
Result:	Elevated LC3B-II (a marker to monitor autophagy) and SQSTM1 protein levels in a concentration- and time-dependent manner.

体内研究
(In Vivo)

CA-5f (40 mg/kg, i.p., every 2 days for up to 30 days) is well tolerated, and potently inhibits the growth of tumor in nude mice bearing A549 lung cancer cells.
CA-5f (40 mg/kg, i.p.) suppresses autophagic flux and induces apoptosis in nude mice bearing A549 lung cancer cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing A549 lung cancer cells
Dosage:	40 mg/kg
Administration:	Injected via caudal vein, every 2 days for up to 30 days
Result:	Significantly suppressed tumor volume and weight in mice, increased the number of apoptotic cells in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing A549 lung cancer cells
Dosage:	40 mg/kg
Administration:	Injected via caudal vein, every 2 days for up to 30 days
Result:	Significantly suppressed tumor volume and weight in mice, increased the number of apoptotic cells in mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing A549 lung cancer cells
Dosage:	40 mg/kg
Administration:	Injected via caudal vein, every 2 days for up to 30 days
Result:	Significantly suppressed tumor volume and weight in mice, increased the number of apoptotic cells in mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : 77.5 mg/mL (199.51 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.5743 mL	12.8713 mL	25.7427 mL
5 mM	0.5149 mL	2.5743 mL	5.1485 mL
10 mM	0.2574 mL	1.2871 mL	2.5743 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.35 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.35 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (5.35 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.35 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.35 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.35 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。